Monday, October 23, 2017
Last Friday, Dyadic CEO, Mark Emalfarb, gave an online investor presentation at a Virtual Investors Conference. The presentation was well done in that it really made the case for C1 as a disruptive technology for the biologics industry. If...
Mark Emalfarb, the Chairman and CEO of Dyadic International, discusses the status of the  Company's revolutionary C1 protein expression host.
Dyadic International is a progressive and interesting company in more ways than one. Founded by Mark Emalfarb in 1979, this commercially proven gene expression company has its roots in industrial biotechnology where Mark Emalfarb pioneered the use of pumice...
JUPITER, Fla., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (DYAI) (“Dyadic”) announced that its Board of Directors has authorized a new stock repurchase program, under which the Company may repurchase up to $5 million of its outstanding...
On Friday, August 4, 2017, we added Dyadic International (DYAI) to The Tailwinds Select Portfolio at a price of $1.34 per share. Dyadic International, Inc. is a biotechnology company focused on the development of enzymes and other proteins that enable...
UPITER, FL – July 10, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), announced today that it has entered into a comprehensive series of research and development agreements, including a potential commercialization agreement, with Biotechnology Development for Industry...
UPITER, FL – July 6, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), is pleased to announce that it has received approximately $7.4 million from the escrow account established in connection with the sale of assets of Dyadic’s...
JUPITER, FL – May 25, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), announced today that its Chairman of the Board, Michael P. Tarnok, and its Audit Committee Chair, Jack L. Kaye, have purchased 50,000 and 35,000 shares of...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address